

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Suzhou Basecare Medical Corporation Limited**  
**蘇州貝康醫療股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2170)**

**COMPLETION OF THE H SHARE FULL  
CIRCULATION PROGRAMME BY A SHAREHOLDER**

Reference is made to the announcements of Suzhou Basecare Medical Corporation Limited (the “**Company**”) dated August 20, 2021, February 24, 2022 and March 6, 2022 (the “**Announcements**”) in relation to the Company’s participation in the H Share full circulation programme. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

**COMPLETION OF THE H SHARE FULL CIRCULATION PROGRAMME  
BY A SHAREHOLDER**

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that the conversion of 1,780,417 unlisted foreign shares held by Orbimed Partners Master Fund Limited (“**Orbimed**”) into H Shares (the “**Converted H Shares**”) was completed on September 9, 2022.

As disclosed in the Company’s announcements dated February 24, 2022 and March 6, 2022, the Company obtained the approvals from CSRC and the Stock Exchange for the Conversion and Listing for up to 192,592,582 Unlisted Shares held by 16 Participating Shareholders. The listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on September 13, 2022.

## SHAREHOLDING STRUCTURE

The share capital structure of the Company immediately before and upon the completion of the Conversion and Listing by Orbimed is set out below:

Class of shares	Immediately before completion of the Conversion and Listing by Orbimed		Upon completion of the Conversion and Listing by Orbimed	
	<i>Number of shares</i>	<i>Approximate percentage</i>	<i>Number of shares</i>	<i>Approximate percentage</i>
Domestic shares	183,181,817	66.97%	183,181,817	66.97%
Unlisted foreign shares	9,410,765	3.44%	7,630,348	2.79%
H Shares	80,933,418	29.59%	82,713,835	30.24%
Total number of issued shares	<u>273,526,000</u>	<u>100.00%</u>	<u>273,526,000</u>	<u>100.00%</u>

By order of the Board  
**Suzhou Basecare Medical Corporation Limited**  
**Dr. Liang Bo**  
*Chairman and General Manager*

Suzhou, PRC, September 9, 2022

*As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. CHAU Kwok Keung as independent non-executive Directors.*